329.77
price up icon2.39%   7.71
after-market Handel nachbörslich: 329.77
loading
Schlusskurs vom Vortag:
$322.06
Offen:
$319.62
24-Stunden-Volumen:
967.74K
Relative Volume:
0.96
Marktkapitalisierung:
$39.44B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$-269.70M
KGV:
-157.78
EPS:
-2.09
Netto-Cashflow:
$-75.39M
1W Leistung:
+2.43%
1M Leistung:
+7.74%
6M Leistung:
+41.16%
1J Leistung:
+33.18%
1-Tages-Spanne:
Value
$319.40
$330.00
1-Wochen-Bereich:
Value
$315.00
$330.00
52-Wochen-Spanne:
Value
$205.87
$330.00

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Name
Firmenname
Alnylam Pharmaceuticals Inc
Name
Telefon
(617) 551-8200
Name
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Name
Mitarbeiter
2,230
Name
Twitter
@alnylam
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
ALNY's Discussions on Twitter

Vergleichen Sie ALNY mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-31 Eingeleitet Redburn Atlantic Buy
2025-03-24 Hochstufung JP Morgan Neutral → Overweight
2024-11-12 Herabstufung Wolfe Research Peer Perform → Underperform
2024-10-16 Eingeleitet Scotiabank Sector Outperform
2024-08-16 Hochstufung Goldman Neutral → Buy
2024-02-16 Herabstufung Goldman Buy → Neutral
2024-02-15 Eingeleitet Wolfe Research Peer Perform
2023-12-08 Eingeleitet Wells Fargo Equal Weight
2023-10-11 Herabstufung Oppenheimer Outperform → Perform
2023-09-29 Eingeleitet Raymond James Outperform
2023-05-05 Hochstufung BMO Capital Markets Market Perform → Outperform
2023-04-26 Eingeleitet SMBC Nikko Neutral
2023-03-21 Eingeleitet Bernstein Outperform
2023-01-18 Eingeleitet Canaccord Genuity Buy
2022-09-09 Fortgesetzt Morgan Stanley Equal-Weight
2022-07-13 Eingeleitet Cantor Fitzgerald Neutral
2022-06-27 Herabstufung Guggenheim Buy → Neutral
2022-06-07 Eingeleitet William Blair Outperform
2022-04-25 Herabstufung Morgan Stanley Overweight → Equal-Weight
2022-03-01 Eingeleitet Citigroup Buy
2022-02-03 Hochstufung Guggenheim Neutral → Buy
2022-01-03 Hochstufung Piper Sandler Neutral → Overweight
2021-11-22 Hochstufung Goldman Neutral → Buy
2021-11-22 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2021-11-01 Hochstufung Oppenheimer Perform → Outperform
2021-10-04 Hochstufung UBS Neutral → Buy
2021-08-04 Herabstufung Piper Sandler Overweight → Neutral
2021-02-22 Herabstufung Guggenheim Buy → Neutral
2021-02-12 Herabstufung Citigroup Buy → Neutral
2021-02-12 Bestätigt H.C. Wainwright Buy
2021-01-25 Herabstufung BMO Capital Markets Outperform → Market Perform
2020-09-30 Fortgesetzt Berenberg Hold
2020-09-08 Eingeleitet Citigroup Buy
2020-08-11 Herabstufung Oppenheimer Outperform → Perform
2020-05-13 Eingeleitet RBC Capital Mkts Sector Perform
2020-05-07 Herabstufung JP Morgan Overweight → Neutral
2020-04-24 Fortgesetzt Evercore ISI Outperform
2020-03-19 Eingeleitet Berenberg Buy
2019-12-19 Bestätigt Chardan Capital Markets Buy
2019-11-20 Eingeleitet Oppenheimer Outperform
2019-11-13 Eingeleitet BofA/Merrill Buy
2019-05-23 Fortgesetzt Goldman Neutral
2019-04-12 Eingeleitet Evercore ISI Outperform
2019-03-06 Hochstufung Evercore ISI In-line → Outperform
2019-03-05 Hochstufung Morgan Stanley Equal-Weight → Overweight
2019-01-23 Eingeleitet UBS Neutral
2018-10-01 Eingeleitet Cantor Fitzgerald Overweight
2018-08-13 Bestätigt Stifel Buy
2018-08-07 Hochstufung Stifel Hold → Buy
2018-05-04 Bestätigt Stifel Hold
2018-03-28 Eingeleitet Evercore ISI In-line
Alle ansehen

Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten

pulisher
Jun 18, 2025

Alnylam Pharma Appoints New Chief R&D Officer - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Alnylam Announces Promotion of Pushkal Garg as Executive Vice President and Chief Research and Development Officer - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Alnylam Promotes Pushkal Garg to Chief Research and Development Officer - citybiz

Jun 18, 2025
pulisher
Jun 18, 2025

Alnylam appoints Pushkal Garg as chief research and development officer - Investing.com Australia

Jun 18, 2025
pulisher
Jun 18, 2025

Alnylam appoints Pushkal Garg as chief research and development officer By Investing.com - Investing.com Nigeria

Jun 18, 2025
pulisher
Jun 18, 2025

Alnylam (ALNY) Names New Chief R&D Officer to Drive Innovation | - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Alnylam Announces Promotion of Pushkal Garg to Chief Research an - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer - Business Wire

Jun 18, 2025
pulisher
Jun 18, 2025

Alnylam Pharmaceuticals stock hits all-time high at $311.24 By Investing.com - Investing.com Canada

Jun 18, 2025
pulisher
Jun 17, 2025

Global RNAi Technology Market: Opportunities in Targeted - openPR.com

Jun 17, 2025
pulisher
Jun 17, 2025

Japan’s Isshiki bolsters life sciences practice with senior hire - | Asian Legal Business

Jun 17, 2025
pulisher
Jun 16, 2025

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years - Benzinga

Jun 16, 2025
pulisher
Jun 16, 2025

Antisense Oligonucleotides Market is expected to reach US$ - openPR.com

Jun 16, 2025
pulisher
Jun 16, 2025

Exploring High Growth Tech Stocks In The US This June 2025 - simplywall.st

Jun 16, 2025
pulisher
Jun 14, 2025

Alnylam Pharmaceuticals’ SWOT analysis: stock poised for growth in expanding ATTR-CM market - Investing.com Canada

Jun 14, 2025
pulisher
Jun 13, 2025

Acute Intermittent Porphyria Market Predicted to See Upsurge - openPR.com

Jun 13, 2025
pulisher
Jun 13, 2025

From Kentucky farm to founding Biogen: New documentary traces life of Phil Sharp - The Business Journals

Jun 13, 2025
pulisher
Jun 12, 2025

Where are the Opportunities in (ALNY) - news.stocktradersdaily.com

Jun 12, 2025
pulisher
Jun 12, 2025

Primary Hyperoxaluria Pipeline 2025: FDA Updates, Therapy - openPR.com

Jun 12, 2025
pulisher
Jun 12, 2025

Healey boosts life sciences tax incentives as 33 companies plan major expansions - The Business Journals

Jun 12, 2025
pulisher
Jun 12, 2025

ALNY Stock: JP Morgan Raises Price Target to $338 | ALNY Stock N - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

What 18 Analyst Ratings Have To Say About Alnylam Pharmaceuticals - Benzinga

Jun 12, 2025
pulisher
Jun 12, 2025

Homozygous Familial Hypercholesterolemia Market to Reach New - openPR.com

Jun 12, 2025
pulisher
Jun 12, 2025

Homozygous Familial Hypercholesterolemia Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Arrowhead Pharma, Novartis, Alnylam Pharma, LIB Therapeutics, Amryt Pharma - The Globe and Mail

Jun 12, 2025
pulisher
Jun 12, 2025

JPMorgan Ups Price Target for Alnylam (ALNY) Following Amvuttra Forecast Revision | ALNY Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 11, 2025

Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM - MSN

Jun 11, 2025
pulisher
Jun 11, 2025

The European Commission Approves Alnylam’s AMVUTTRA - Insider Monkey

Jun 11, 2025
pulisher
Jun 11, 2025

John Maraganore joins Axion Bio board to advance cancer therapy By Investing.com - Investing.com Canada

Jun 11, 2025
pulisher
Jun 11, 2025

Former Alnylam CEO Who Built $40B Company Backs Instil Bio's Novel Cancer Drug Program - Stock Titan

Jun 11, 2025
pulisher
Jun 10, 2025

EC approves Alnylam’s vutrisiran for ATTR-CM treatment - Yahoo Finance

Jun 10, 2025
pulisher
Jun 09, 2025

Latest Federal Court Cases: Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. - JD Supra

Jun 09, 2025
pulisher
Jun 09, 2025

Dyslipidemia Market to Reach New Heights in Growth by 2034, - openPR.com

Jun 09, 2025
pulisher
Jun 09, 2025

Alnylam gets EU approval for Amvuttra in heart disorder treatment - MSN

Jun 09, 2025
pulisher
Jun 09, 2025

Alnylam Receives European Commission Approval for AMVUTTRA® (vut - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

European Approval Expansion for Alnylam's (ALNY) AMVUTTRA | ALNY Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Alnylam (ALNY) Secures EU Approval for Amvuttra in Cardiomyopathy - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Transcript : Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09 - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

Alnylam Gets EU Approval for RNAi Drug to Treat Transthyretin Amyloidosis With Cardiomyopathy - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

EC approves first RNAi therapy for ATTR cardiomyopathy By Investing.com - Investing.com Nigeria

Jun 09, 2025
pulisher
Jun 09, 2025

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy | ALNY Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

(vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy - Business Wire

Jun 09, 2025
pulisher
Jun 09, 2025

siRNA on the Precipice as Candidates Reach Beyond the Liver - BioSpace

Jun 09, 2025
pulisher
Jun 07, 2025

AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B - mx.advfn.com

Jun 07, 2025
pulisher
Jun 07, 2025

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alnylam Pharmaceuticals, Inc. (ALNY) - ACCESS Newswire

Jun 07, 2025
pulisher
Jun 06, 2025

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY) - ACCESS Newswire

Jun 06, 2025
pulisher
Jun 06, 2025

Alnylam, Incyte and GSK led biopharma gains amid earnings volatility - BioWorld MedTech

Jun 06, 2025
pulisher
Jun 05, 2025

Fed Circ upholds Moderna’s COVID-19 vaccine win against Alnylam - Life Sciences Intellectual Property Review

Jun 05, 2025
pulisher
Jun 05, 2025

Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case - Benzinga

Jun 05, 2025
pulisher
Jun 04, 2025

Alnylam Fails to Revive Patent Infringement Suit Against Moderna - Bloomberg Law News

Jun 04, 2025
pulisher
Jun 04, 2025

Strict Standard for Overriding Patent Lexicography in COVID Vaccine Patent Battle - Patently-O

Jun 04, 2025
pulisher
Jun 04, 2025

CAFC Affirms Moderna’s Win, Holding Alnylam Narrowly Defined ‘Branched Alkyl’ - IPWatchdog.com

Jun 04, 2025

Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Alnylam Pharmaceuticals Inc-Aktie (ALNY) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Greenstreet Yvonne
Chief Executive Officer
Jun 02 '25
Option Exercise
118.73
19,297
2,291,057
68,245
Greenstreet Yvonne
Chief Executive Officer
May 30 '25
Sale
304.39
31,640
9,630,902
48,948
Greenstreet Yvonne
Chief Executive Officer
Jun 02 '25
Sale
306.00
19,297
5,904,882
48,948
$545.11
price up icon 0.49%
biotechnology ONC
$244.32
price down icon 0.34%
$108.26
price up icon 0.70%
$547.74
price up icon 2.40%
$98.24
price up icon 0.64%
Kapitalisierung:     |  Volumen (24h):